Steroids in Hem/Onc

Overview & Classification

Corticosteroids are among the most widely used agents in hematology/oncology — serving as chemotherapeutic backbones, supportive agents, anti-emetics, and immunosuppressants. They exert effects through both genomic (hours) and non-genomic (minutes) pathways.^1,2

Relative Potency Comparison^3,4

Agent	Anti-inflammatory potency	Mineralocorticoid potency	Equivalent dose	Plasma half-life	Biologic half-life
Hydrocortisone	1 (reference)	1	20 mg	1.5–2 h	8–12 h
Prednisone	4	0.25	5 mg	3.4–3.8 h	18–36 h
Prednisolone	4	0.25	5 mg	2–3 h	18–36 h
Methylprednisolone	5	0.5	4 mg	1.8–5.2 h	18–36 h
Dexamethasone	25–30	0 (negligible)	0.75 mg	1.8–3.5 h	36–54 h

💡 Key concept

Dexamethasone has ZERO mineralocorticoid activity → less fluid retention than prednisone or hydrocortisone.
This matters in myeloma patients who are often elderly with cardiovascular comorbidities.

Why do steroids work in cancer?

Mechanism of Action

Genomic pathway (primary)¹

Key downstream effects in Hem/Onc^5,6,9

Effect	Mechanism	Clinical relevance
Lymphocyte apoptosis	Upregulates BIM (pro-apoptotic BH3-only protein); suppresses BCL-2 family	Core cytotoxic mechanism in ALL, DLBCL, MM, CLL
NF-κB inhibition	GR directly interacts with NF-κB subunits; upregulates IκBα	Anti-inflammatory + anti-tumor in lymphoid neoplasms
IL-6 suppression	Transcriptional repression of IL-6 gene	Critical in MM — IL-6 is primary myeloma growth/survival factor
VEGF suppression	Reduce VEGF transcription	Anti-angiogenic; reduces tumor vascularity
T-cell suppression	Reduce T-cell proliferation; shift Th1→Th2; reduce IL-2	GVHD treatment; but also explains infectious risk
Myelopoiesis stimulation	Demargination of neutrophils; inhibit CXCR4	Neutrophilia after steroid (can confuse CBC interpretation!)

⚠️ Steroid resistance¹⁰

Emerges via GR mutations (GR-β isoform overexpression), upregulation of anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1), or efflux pumps (MDR1/P-glycoprotein).
Common in relapsed ALL and MM.

Non-genomic pathway (rapid effects, minutes)¹¹

Mediated via membrane-bound GRs and second messenger cascades. Explains rapid anti-emetic effects, rapid anti-inflammatory effects at high doses, and immediate hemodynamic effects in high-dose pulses.

Pharmacokinetics^3,4,12

Parameter	Prednisone	Prednisolone	Methylprednisolone	Dexamethasone
Prodrug?	Yes → prednisolone (hepatic 11β-HSD)	No (active)	No	No
Bioavailability PO	~80%	~80–90%	~82–90%	~70–80%
Protein binding	70–90% (albumin, CBG)	70–90%	~40–90%	~68% (albumin)
Volume of distribution	0.4–1.0 L/kg	0.5 L/kg	1.2–1.5 L/kg	0.8–1.0 L/kg
Metabolism	Hepatic (CYP3A4)	Hepatic (CYP3A4)	Hepatic (CYP3A4)	Hepatic (CYP3A4)
Plasma T½	3.4–3.8 h	2–3 h	1.8–5.2 h	1.8–3.5 h
Biologic T½ (HPA effect)	18–36 h	18–36 h	18–36 h	36–54 h
CNS penetration	Moderate	Moderate	Good	Excellent (lipophilic)
Renal adjustment	Not required	Not required	Not required	Not required
Hepatic impairment	Avoid severe — impaired conversion	Use prednisolone (active)	Use with caution	Use with caution

⚠️ Prednisone in liver failure¹³

Prednisone requires hepatic conversion to prednisolone
(active form). In severe hepatic impairment (cirrhosis, VOD/SOS post-transplant), use prednisolone directly to ensure adequate drug levels.

Dexamethasone: why it dominates in myeloma and CNS disease^3,14

• Longer biologic half-life (36–54 h) → less frequent dosing
• Highest anti-inflammatory potency (25–30× hydrocortisone)
• Zero mineralocorticoid activity → less fluid retention (crucial in elderly MM patients)
• Excellent CNS penetration (lipophilic) → CSF levels ~4× higher than prednisone equivalent dose
• No prodrug conversion needed

Regimens by Disease

Toxicities

In hematologic malignancies, patients often receive prolonged, high-dose steroids in combination with immunosuppressants — this dramatically amplifies all toxicities below.

Short-term toxicities (days to weeks)

Toxicity	Incidence	Management	Reference
Hyperglycemia	~40–50% in non-diabetics; higher in diabetics	FSBS monitoring; insulin correction scales; consider insulin regimen in persistent hyperglycemia. Dexamethasone causes prolonged post-prandial hyperglycemia.	Kwon S & Hermayer KL. Am J Med Sci. 2013;345(4):274–277
Insomnia / neuropsychiatric	Up to 50% (mood changes, anxiety, depression, mania)	Take AM doses (avoid PM); consider low-dose olanzapine or quetiapine; dose reduction if severe. Dexamethasone > prednisone for CNS effects.	Bhatt M et al. Oncology. 2018;32(1)
Fluid retention / edema	Common with prednisone (mineralocorticoid effect)	Dietary sodium restriction; loop diuretics PRN. Dexamethasone has minimal effect.	UpToDate 2024
GI distress / ulceration	Increased when combined with NSAIDs (~15-fold risk increase)	PPI (omeprazole 20 mg daily) if concurrently on NSAIDs or anticoagulants. Steroids alone do NOT routinely require PPI.	Piper JM et al. Ann Intern Med. 1991;114(9):735–740 | ACG Guidelines 2022
Leukocytosis (neutrophilia)	WBC may rise 5,000–20,000/μL within 24–48 h	Do NOT interpret as infection if temporally related to steroid initiation. Lymphopenia also common.	Shoenfeld Y et al. JAMA. 1981;245(15):1545–1549
Hypertension	Common; dose-dependent	BP monitoring; antihypertensives as needed	UpToDate 2024
Appetite increase / weight gain	Very common	Dietary counseling	FDA PI
Hypokalemia	More with hydrocortisone/prednisone (mineralocorticoid); less with dexamethasone	Electrolyte monitoring; oral KCl supplementation	UpToDate 2024

Long-term toxicities (weeks to months)

Toxicity	Threshold / Risk factors	Management / Prevention	Reference
Osteoporosis / fractures	Any dose >5 mg prednisone equivalent /day >3 months	Calcium 1000–1200 mg/day + Vitamin D 600–800 IU/day + Bisphosphonate (alendronate, zoledronic acid) for moderate/high fracture risk per FRAX. DEXA scan at baseline and every 1–2 years.	ACR Glucocorticoid-Induced Osteoporosis Guidelines 2022 (Buckley L et al.)
Avascular necrosis (AVN / osteonecrosis)	Cumulative dose, high single doses; dexamethasone in MM patients >40 y/o	No proven prevention. Early MRI if hip/shoulder/knee pain. Orthopedics consult. Core decompression for early AVN.	Miller KD et al. Ann Intern Med. 1998;128(3):207–213 | Shah M et al. Leukemia. 2004
HPA axis suppression / adrenal insufficiency	≥20 mg prednisone eq./day for ≥3 weeks	Gradual tapering. Stress dosing during surgery/illness (hydrocortisone 50–100 mg IV q8h). Morning cortisol or ACTH stimulation test if concerned.	Dinsen S et al. Eur J Intern Med. 2013;24(6):499–503
Myopathy (proximal)	Higher risk with fluorinated steroids (dexamethasone, triamcinolone) >weeks	Dose reduction; physical therapy. Distinguishing from disease-related weakness can be challenging.	Pereira RM & Freire de Carvalho J. Autoimmune Rev. 2011;10(9):563–570
Cataracts (posterior subcapsular)	Duration-dependent	Annual ophthalmology evaluation in patients on prolonged steroids	Cumming RG et al. NEJM. 1997;337(1):8–14
Cushing’s syndrome	Prolonged moderate-high dose	Dose minimization; use lowest effective dose	UpToDate 2024
Immunosuppression / infections	Prednisone ≥20 mg/day ≥4 weeks; combined immunosuppression	See Prophylaxis tab	ASCO OI Prevention Guidelines 2018
VTE (with IMiDs)	IMiD + steroid → HIGH VTE risk (up to 25% without prophylaxis)	See Prophylaxis tab	Palumbo A et al. Leukemia. 2008;22(2):414–423

AVN in myeloma: High-dose dexamethasone regimens (old HD-Dex) carried ~7–10% cumulative AVN risk. Even with low-dose dex, AVN occurs in ~5–7% of MM patients over their disease course. Educate patients to report new joint pain immediately.⁴⁷

Prophylaxis with Steroids

Steroid Taper / Adrenal Insufficiency Prevention+

If steroids ≥20 mg prednisone equivalent/day for ≥3 weeks: taper gradually rather than abrupt discontinuation to allow HPA axis recovery.^60,61

• Reduce by 10 mg/day every 1–2 weeks until reaching 20 mg/day, then reduce by 2.5–5 mg every 2–4 weeks
• Physiologic replacement dose: ~5–7.5 mg prednisone/day (or 10–20 mg hydrocortisone/day)
• Stress dose steroids (surgery/illness): hydrocortisone 50–100 mg IV q8h → taper over 1–3 days

Drug Interactions

Dexamethasone is a moderate CYP3A4 INDUCER. This is highly relevant in myeloma where many novel agents are CYP3A4 substrates.

Drug / class62,63,64,65,66	Interaction with steroids	Mechanism	Clinical action
Azole antifungals (posaconazole, voriconazole, itraconazole, fluconazole)	↑ Steroid levels 2–6×	CYP3A4 inhibition → reduced steroid metabolism	Reduce steroid dose when adding azoles (e.g., dexamethasone anti-emetic dose halved when NK1 used concomitantly). Monitor for Cushingoid features.
Ibrutinib (BTK inhibitor)	Dex ↓ ibrutinib levels	Dex induces CYP3A4 → ↑ ibrutinib metabolism	Avoid concomitant use if possible; if necessary, monitor clinical response
Venetoclax	Dex ↓ venetoclax levels by ~50%	CYP3A4 induction	Avoid strong CYP3A4 inducers with venetoclax. Use alternative steroid (prednisolone less inducing) or timing separation if unavoidable.
Warfarin	Variable; may ↑ or ↓ INR	Multiple mechanisms	Increase INR monitoring frequency when steroids started/stopped
NSAIDs	↑ GI ulceration and bleeding risk (~15×)	Synergistic mucosal injury	Avoid combination; if necessary, add PPI
Live vaccines	Risk of disseminated vaccine infection	Immunosuppression	Contraindicated in patients on immunosuppressive steroid doses (>20 mg prednisone/day for >2 weeks)
Insulin / antidiabetics	Reduced hypoglycemic effect; ↑ blood glucose	Steroid-induced insulin resistance / gluconeogenesis	Increase insulin doses; monitor glucose. Dexamethasone causes predominantly post-prandial hyperglycemia → NPH insulin or rapid-acting prandial insulin preferred over basal-only adjustment.
Fluoroquinolones (ciprofloxacin, levofloxacin)	↑ tendon rupture risk	Synergistic tendinopathy	Counsel patients; avoid prolonged combination if possible
Cyclosporine / tacrolimus	↑ Immunosuppression; cyclosporine levels variable (CYP3A4 interaction)	CYP3A4 interaction; additive immunosuppression	Monitor calcineurin inhibitor levels; monitor for opportunistic infections
Amphotericin B	↑ Hypokalemia	Additive electrolyte wasting	Frequent electrolyte monitoring; KCl supplementation
Diuretics (loop, thiazide)	↑ Hypokalemia	Additive electrolyte loss	Monitor K+; supplement PRN

Dexamethasone + posaconazole (commonly co-prescribed in AML or HSCT patients): Posaconazole inhibits CYP3A4 → dexamethasone AUC increases significantly. This combination is frequently used but requires dose reduction of dexamethasone (e.g., for anti-emesis or anti-inflammatory use) and careful monitoring for steroid side effects.^67,68

Monitoring Parameters

Inpatient — acute/intensive phase^69,70,71

• Blood glucose: Q6–8h (or per sliding scale); daily in stable patients
• Blood pressure: Q shift
• Weight / fluid balance: Daily (fluid retention, especially prednisone)
• Electrolytes (K+, Na+, Mg2+): Daily if receiving amphotericin, loop diuretics, or vomiting
• CBC: Monitor for stress leukocytosis (can mislead) and lymphopenia
• Neuropsychiatric symptoms: Daily assessment; note sleep quality
• Infection signs: Temperature, CRP, signs of fungal/bacterial infection

Outpatient — chronic therapy^69,70,71

• HbA1c + fasting glucose: Baseline, then every 3–6 months
• Blood pressure: Every visit
• Weight: Every visit
• DEXA scan: Baseline (if on steroids ≥3 months expected); repeat every 1–2 years
• Ophthalmology: Annual (cataracts, glaucoma)
• Lipid panel: Annually (steroid dyslipidemia)
• Morning cortisol / ACTH stim test: If adrenal insufficiency suspected
• Hip/shoulder/joint pain assessment: Each visit (AVN early detection)

Hyperglycemia management in inpatient setting

Steroid-induced hyperglycemia pattern differs by steroid type. This has major implications for insulin selection.

Steroid72,73,74	Hyperglycemia pattern	Preferred insulin approach
Prednisone (daily AM dose)	Post-lunch and afternoon peak; normal fasting	NPH insulin in AM (peaks 4–6 h, covers PM) OR prandial rapid-acting insulin at lunch/dinner
Dexamethasone (long-acting, 36–54 h biologic T½)	Prolonged, all-day elevation; fasting hyperglycemia also common	Basal insulin (glargine/ detemir) + prandial correction; avoid NPH only
Methylprednisolone IV (pulse)	Severe acute hyperglycemia, all-day	Insulin drip (ICU) or aggressive subcutaneous correction scale; basal-bolus regimen

Pharmacist Watchouts

Prednisone requires hepatic activation → use prednisolone in liver failure

Prednisone is a prodrug converted by hepatic 11β-HSD1 to prednisolone. In significant hepatic dysfunction (e.g., SOS/VOD post-HSCT, cirrhosis, severe liver metastases), this conversion is impaired → inadequate active drug. Switch to prednisolone 1:1 (same dose in mg).¹³

Low-dose dexamethasone is the standard in MM — do NOT use HD-Dex regimens

ECOG E4A03 demonstrated LD-Dex (40 mg weekly) superior OS (1-yr OS 96% vs 88%, p<0.01) and significantly less toxicity vs HD-Dex (40 mg days 1-4, 9-12, 17-20). HD-Dex was associated with higher rates of DVT, serious infections, and early deaths. If you see a HD-Dex order in a newly diagnosed MM patient, question it.²¹

Dexamethasone + azole antifungals = significantly increased steroid exposure

Posaconazole/voriconazole inhibit CYP3A4 → dexamethasone AUC ↑ 2–6×. This is common in myeloma (dex + len + posaconazole). Patients present with Cushingoid features, worsening hyperglycemia, severe insomnia. Reduce dex dose when adding azoles.⁶⁸

Dexamethasone reduces venetoclax levels (CYP3A4 induction)

This is critical for venetoclax-based regimens. In AML (Ven-AZA) or CLL (Ven-R), concurrent use of dexamethasone (even for anti-emesis) can reduce venetoclax efficacy. If steroid anti-emesis needed, consider short course or alternative agents.

In patients with relapsed or refractory multiple myeloma, an increase in mortality was noted when venetoclax was added to bortezomib and dexamethasone (in patients without the t(11;14) translocation [Kumar 2020]). Relapsed/refractory t(11;14) multiple myeloma is an off-label use for venetoclax.^75,76

VTE prophylaxis in IMiD-based regimens is mandatory — not optional

Lenalidomide/thalidomide + dexamethasone combinations carry up to 25% VTE risk without prophylaxis. Always verify VTE prophylaxis order. Risk-stratify: aspirin 81–325 mg (low risk) vs LMWH/warfarin (high risk: prior VTE, immobility, multi-agent, obesity, EPO, high-dose dex).^53,25

PCP prophylaxis thresholds in steroid-containing regimens

Trigger: ≥20 mg/day prednisone equivalent for ≥4 weeks AND + another immunosuppressant (rituximab, alkylator, fludarabine). TMP-SMX DS 3×/week is first-line. Check: sulfa allergy, G6PD status before choosing alternative (dapsone → hemolysis in G6PD deficiency).^48,50

Steroid-induced hyperglycemia: type of steroid determines insulin strategy

AM prednisone → afternoon peak → NPH AM preferred. Dexamethasone → all-day effect → basal-bolus preferred. Do NOT assume one sliding scale works for all steroids. Coordinate with endocrinology/diabetes team for patients with known DM or persistent FSBS >180 mg/dL.⁷²

Steroid taper is required if ≥3 weeks at ≥20 mg prednisone — abrupt stop = adrenal crisis risk

Gradual taper schedule required. In emergency (patient unable to take PO, surgery, illness, sepsis): stress-dose hydrocortisone 50–100 mg IV q8h. Always provide a written taper schedule to patients on discharge. Educate: do not stop suddenly.⁶⁰

Bone protection → initiate at therapy start, not retrospectively

If patient will be on ≥5 mg prednisone equivalent for ≥3 months: start calcium + Vit D + assess FRAX score at initiation. In myeloma: zoledronic acid (or denosumab if eGFR <30) is standard regardless of steroids for bone protection. Do not wait for osteoporosis to be “documented.”^56,77

10. Steroid leukocytosis ≠ infection

WBC can rise 5,000–20,000/μL within 24–48 h of steroid initiation due to neutrophil demargination (not shift in production). Concurrent lymphopenia is expected. Alert prescribers who may incorrectly diagnose and treat “infection.” Context is everything.⁷⁸

Handouts

📖 References

1. Coutinho AE & Chapman KE. Mol Cell Endocrinol. 2011;335(1):2–13
2. Oakley RH & Cidlowski JA. J Biol Chem. 2013;288:22361–22369
3. Czock D et al. Clin Pharmacokinet. 2005;44(1):61–98
4. UpToDate: “Pharmacology of corticosteroids” 2024
5. Herold MJ et al. Blood. 2006;108(11):3609–3616
6. Hideshima T et al. Oncogene. 2001;20:4519
7. ASCO/MASCC Antiemesis Guidelines 2020
8. Roila F et al. Ann Oncol. 2016;27(suppl 5):v119–v133
9. Newton R. Thorax. 2000;55:603–613
10. Schmidt S et al. Leukemia. 2004;18:1835–1845
11. Löwenberg M et al. Steroids. 2008;73:1016–1021
12. FDA Prescribing Information: Decadron, Solu-Medrol, Deltasone
13. Frey BM & Frey FJ. Clin Pharmacokinet. 1990;19(4):285–308
14. Veal GJ et al. Clin Pharmacokinet. 2003;42(6):557–574
15. Coiffier B et al. NEJM. 2002;346(4):235–242
16. Wilson WH et al. NEJM. 2012;367(15):1397–1408
17. NCCN B-Cell Lymphomas v5.2024
18. Engert A et al. NEJM. 2010;363(7):640–652 (HD18 GHSG trial)
19. Moskowitz CH et al. Blood. 1999;93(10):3469–3477
20. Josting A et al. Ann Oncol. 2002;13(10):1628–1635
21. Rajkumar SV et al. Lancet Oncol. 2010;11(1):29–37
22. Durie BGM et al. SWOG S0777. NEJM 2017
23. Facon T et al. MAIA. NEJM 2019
24. Dimopoulos M et al. CASTOR. NEJM 2016
25. NCCN Multiple Myeloma v4.2025
26. IMWG Frailty Score
27. Palumbo A et al. Leukemia. 2015;29(9):1820–1827
28. Bostrom BC et al. CCG-1961. Blood. 2003;101(10):3809–3817
29. Mitchell C et al. Blood. 2005;106(7):2428–2433
30. NCCN Acute Lymphoblastic Leukemia v1.2025
31. Stock W et al. Blood. 2019;133(14):1548–1559
32. Magrath I et al. JCO. 1996;14(3):925–934
33. Kantarjian HM et al. JCO. 2004;22(7):1209–1218
34. Castro JE et al. Leukemia. 2008;22(11):2048–2053
35. NCCN CLL/SLL v2.2025
36. Ruutu T et al. Bone Marrow Transplant. 2014;49(2):168–173 (EBMT/ELN guidelines)
37. Martin PJ et al. Biol Blood Marrow Transplant. 2012;18(8):1150–1163
38. Zeiser R et al. REACH2. NEJM. 2020;382(19):1800–1810
39. Flowers MED & Martin PJ. Hematology ASH Education Book. 2015;2015(1):98–107
40. Neunert C et al. ASH ITP Guidelines. Blood. 2019;133(23):2386–2393
41. Provan D et al. Blood Adv. 2019;3(22):3780–3817
42. Jäger U et al. ASH AIHA Guidelines. Blood Adv. 2020;4(7):1559–1577
43. Hesketh PJ et al. ASCO Antiemesis Guidelines. JCO. 2020;38(24):2782–2797
44. MASCC/ESMO Antiemetic Guidelines 2023
45. Loblaw DA et al. JCO. 2005;23(9):2028–2037 |
46. NCCN Palliative Care v1.2024
47. Shah M et al. Br J Haematol. 2004;126(6):756–761
48. Baden LR et al. ASCO OI Prevention Guidelines. JCO. 2013;31(31):e400–e427
49. Maret-Ouda J et al. JAMA Intern Med. 2018
50. NCCN Prevention of Infections v1.2025
51. Cornely OA et al. ASPECT trial. NEJM. 2007;356(4):348–359
52. NCCN Prevention and Treatment of Cancer-Related Infections v1.2025
53. Palumbo A et al. Leukemia. 2008;22(2):414–423
54. NCCN Multiple Myeloma v4.2025
55. Lyman GH et al. ASH VTE Guidelines. Blood. 2021;138(4):344–380
56. Buckley L et al. ACR GIO Guidelines. Arthritis Rheumatol. 2017;69(8):1521–1537
57. NCCN Bone Health v2.2024
58. Piper JM et al. Ann Intern Med. 1991;114(9):735–740
59. American College of Gastroenterology (ACG) Guidelines 2022
60. Dinsen S et al. Eur J Intern Med. 2013;24(6):499–503
61. Nieman LK. UpToDate. 2024 “Glucocorticoid withdrawal”
62. Lexicomp Drug Interactions 2024
63. Micromedex 2024
64. Lexi-interact
65. FDA Prescribing Information (Decadron, Deltasone)
66. Löscher W & Potschka H. Prog Neurobiol. 2005;76:22–76
67. NCCN Prevention of Infections v1.2025
68. Krishna G et al. Clin Pharmacol Ther. 2009;86(2):187–194
69. Saag KG et al. NEJM. 1994;330(25):1776–1781
70. ACR GIO Guidelines 2022
71. NCCN Supportive Care v2.2024
72. Kwon S & Hermayer KL. Am J Med Sci. 2013;345(4):274–277
73. Jacobs DM et al. Endocr Pract. 2014
74. AACE/ADA Consensus on Inpatient Hyperglycemia 2009
75. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630-1642. doi:10.1016/S1470-2045(20)30525-8 [PubMed 33129376]
76. FDA Venclexta PI 2024
77. Raje N et al. Lancet Oncol. 2018
78. Shoenfeld Y et al. JAMA. 1981;245(15):1545–1549